Assessment Status | Awaiting full HTA submission from Applicant |
HTA ID | 23073 |
Drug | Tremelimumab |
Brand | Imjudo® |
Indication | Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. |
Assessment Process | |
Rapid review commissioned | 06/12/2023 |
Rapid review completed | 11/01/2024 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tremelimumab in combination with durvalumab compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 01/02/2024 |
Pre-submission consultation with Applicant | 26/03/2024 |